Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis

Journal of Cardiothoracic Surgery

Georg Baumgarten¹  Andreas Hoeft¹  Ingo Graeff¹  Maria Wittmann¹  Olaf Boehm¹  Jens-Christian Schewe¹  Nicole Tran¹  Se-Chan Kim¹ 

[1] Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, Bonn, 53127, Germany

关键词: Critical care;    Heparin induced thrombocytopenia;    Argatroban;   

Others  :  1133316
DOI  :  10.1186/s13019-015-0214-0

 received in 2014-08-04, accepted in 2015-01-18,  发布年份 2015

【 摘 要 】

Background

Heparin-induced thrombocytopenia (HIT) causes thromboembolic complications which threaten life and limb. Heparin is administered to virtually every critically ill patient as a protective measure against thromboembolism. Argatroban is a promising alternative anticoagulant agent. However, a safe dose which still provides effective thromboembolic prophylaxis without major bleeding still needs to be identified.

Methods

Critically ill patients (n = 42) diagnosed with HIT at a tertiary medical center intensive care unit from 2005 to 2010 were included in this retrospective analysis. Patient records were perused for preexisting history of HIT, heparin dosage before HIT, argatroban dosage, number of transfusions required, thromboembolic complications and length of ICU stay (ICU LOS). Patients were allocated to Simplified Acute Physiology Scores above and below 30 (SAPS >30, SAPS <30), respectively. For calculations, patients (n = 19) without previous history of HIT were compared to patients (n = 23) with a history of HIT before initiation of argatroban.

Results

The mean initial argatroban dosage was below 0.4 mcg/kg/min regardless of SAPS score. Maintenance dosage had to be increased in patients with SAPS <30 to 0.54 ± 0.248 mcg/kg/min (p >0.05) to achieve effective anticoagulation. No thromboembolic complications were encountered. Argatroban had to be discontinued temporarily in 16 patients for a total of 57 times due to diagnostic or surgical procedures, supratherapeutic aPTT and bleeding without increasing the number of transfusions. A history of HIT was associated with a shorter ICU LOS and significantly reduced transfusion need when compared to patients with no history of HIT. Cost calculation favour argatroban due to increased transfusion needs during heparin administration and increase ICU LOS.

Conclusion

Argatroban can be used at doses < 0.4 mcg/kg/min without an increase in transfusion requirements and at a reduced overall treatment cost compared to heparin.

【 授权许可】

   
2015 Kim et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 5.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH: Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001, 138:22-31.
• [2]Greinacher A, Ittermann T, Bagemuhl J, Althaus K, Furll B, Selleng S, et al.: Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 2010, 8:2025-31.
• [3]Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A: Evaluation of pretest clinical score (4 T”s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4:759-65.
• [4]Cuker A, Gimotty PA, Crowther MA, Warkentin TE: Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012, 120:4160-7.
• [5]Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P: Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005, 94:132-5.
• [6]Kitchens CS: Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. Am J Hematol 2004, 76:69-73.
• [7]Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:311S-37.
• [8]Lee GM, Arepally GM: Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013, 2013:668-74.
• [9]Raschke RA, Curry SC, Warkentin TE, Gerkin RD: Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood ratios, and Bayes theorem. Chest 2013, 144:1269-75.
• [10]Cuker A: Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost 2011, 106:993-4.
• [11]Fabris F, Luzzatto G, Soini B, Ramon R, Scandellari R, Randi ML, et al.: Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med 2002, 252:149-54.
• [12]Berry C, Tcherniantchouk O, Ley EJ, Salim A, Mirocha J, Martin-Stone S, et al.: Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg 2011, 213:10-7. discussion 17
• [13]Link A, Girndt M, Selejan S, Mathes A, Bohm M, Rensing H: Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009, 37:105-10.
• [14]Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY: Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003, 37:652-4.
• [15]Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G: Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004, 24:409-14.
• [16]Beiderlinden M, Treschan TA, Gorlinger K, Peters J: Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007, 41:749-54.
• [17]Cormack GM, Kaufman LJ: Severe heparin-induced thrombocytopenia: when the obvious is not obvious, a case report. J Med Case Reports 2007, 1:13. BioMed Central Full Text
• [18]Doepker B, Mount KL, Ryder LJ, Gerlach AT, Murphy CV, Philips GS: Bleeding risk factors associated with argatroban therapy in the critically ill. J Thromb Thrombolysis 2012, 34:491-8.
• [19]Pratt DS, Kaplan MM: Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000, 342:1266-71.
• [20]Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al.: Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012, 307:2526-33.
• [21]Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, et al.: Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest 2013, 144:1207-15.
• [22]Seigerman M, Cavallaro P, Itagaki S, Chung I, Chikwe J: Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: an analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 2014, 28(1):98-102.
• [23]De A, Roy P, Garg VK, Pandey NK: Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis 2010, 21:57-61.
• [24]Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-63.
• [25]Le Gall JR, Neumann A, Hemery F, Bleriot JP, Fulgencio JP, Garrigues B, et al.: Mortality prediction using SAPS II: an update for French intensive care units. Crit Care 2005, 9:R645-52. BioMed Central Full Text
• [26]Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L: Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006, 21:86-92.
• [27]Saugel B, Phillip V, Moessmer G, Schmid RM, Huber W: Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Crit Care 2010, 14:R90. BioMed Central Full Text
• [28]Fabris F, Luzzatto G, Stefani PM, Girolami B, Cella G, Girolami A: Heparin-induced thrombocytopenia. Haematologica 2000, 85:72-81.
• [29]Nanwa N, Mittmann N, Knowles S, Bucci C, Selby R, Shear N: The direct medical costs associated with suspected heparin-induced thrombocytopenia. Pharmacoeconomics 2011, 29:511-20.
• [30]Greinacher A, Warkentin TE: Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006, 118:165-76.
• [31]Gray A, Wallis DE, Hursting MJ, Katz E, Lewis BE: Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clin Appl Thromb Hemost 2007, 13:353-61.
• [32]Kiser TH, Mann AM, Trujillo TC, Hassell KL: Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. Am J Hematol 2011, 86:267-72.
• [33]Engstrom M, Rundgren M, Schott U: An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time. Acta Anaesthesiol Scand 2010, 54:86-91.